| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.AMJMED.2011.09.010 |
| P8608 | Fatcat ID | release_pgcld6xrirdknju6wobehhphea |
| P932 | PMC publication ID | 3925418 |
| P698 | PubMed publication ID | 22444096 |
| P5875 | ResearchGate publication ID | 221972892 |
| P50 | author | Munther A. Khamashta | Q73418907 |
| Iñaki Sanz | Q91392897 | ||
| Manuel Ramos-casals | Q42646201 | ||
| P2093 | author name string | John H Stone | |
| Xavier Bosch | |||
| P2860 | cites work | Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry | Q42661986 |
| Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus | Q43064210 | ||
| The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation | Q43890768 | ||
| Treatment for lupus, first in 50 years, offers modest benefits, hope to patients | Q44288823 | ||
| Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases | Q45085614 | ||
| B cell biomarkers of rituximab responses in systemic lupus erythematosus. | Q51007054 | ||
| The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. | Q54791103 | ||
| Systemic lupus erythematosus | Q55933861 | ||
| Connective tissue diseases: The conundrum of B cell depletion in SLE | Q57155428 | ||
| Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response | Q57349317 | ||
| A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery | Q80564566 | ||
| B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response | Q81503192 | ||
| Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis | Q83324335 | ||
| Belimumab | Q84007453 | ||
| Current therapies for lupus nephritis in an ethnically heterogeneous cohort | Q94830004 | ||
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients | Q33387348 | ||
| Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study | Q33803763 | ||
| Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections | Q33895391 | ||
| Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). | Q35557832 | ||
| Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label | Q35617617 | ||
| Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial | Q35993027 | ||
| Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials | Q36302240 | ||
| Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome | Q37123206 | ||
| The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus | Q37170754 | ||
| A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus | Q37378350 | ||
| Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study | Q37462538 | ||
| Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases | Q37541561 | ||
| B cells as therapeutic targets in SLE. | Q37603296 | ||
| B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? | Q37641025 | ||
| Re-evaluation of biologic therapies in systemic lupus erythematosus | Q37696945 | ||
| Rituximab therapy in lupus nephritis: current clinical evidence | Q37737138 | ||
| Biologics in the treatment of systemic lupus erythematosus | Q37760766 | ||
| Therapeutic targeting of B cells for rheumatic autoimmune diseases | Q37829817 | ||
| The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus | Q41935106 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 327-336 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | B-cell-depleting therapy in systemic lupus erythematosus | |
| P478 | volume | 125 |
| Q34394509 | A rare case of prototheca algaemia in a patient with systemic lupus erythematosus and recent belimumab infusion |
| Q38903851 | Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. |
| Q26828588 | Antibodies in the pathogenesis of hypertension |
| Q38065216 | B cell encounters with apoptotic cells |
| Q38813104 | B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease |
| Q38131034 | B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress |
| Q93053543 | BANK1 interacts with TRAF6 and MyD88 in innate immune signaling in B cells |
| Q38289398 | Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies |
| Q42356199 | CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity? |
| Q26824580 | Cellular targeting in autoimmunity |
| Q38197287 | Classification criteria and treatment modalities in primary Sjögren's syndrome |
| Q38175351 | Cogan's syndrome--clinical guidelines and novel therapeutic approaches |
| Q51147794 | Detection of epitopes in systemic lupus erythematosus using peptide microarray. |
| Q38291271 | Human effector B lymphocytes express ARID3a and secrete interferon alpha |
| Q38096027 | Importance of reverse signaling of the TNF superfamily in immune regulation. |
| Q35094536 | In-/off-label use of biologic therapy in systemic lupus erythematosus |
| Q49499785 | New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production |
| Q38156069 | Pragmatic approaches to therapy for systemic lupus erythematosus |
| Q38076460 | Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. |
| Q37062514 | Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway |
| Q33829700 | Rationale for B cell targeting in SLE |
| Q45376906 | Screening epitopes on systemic lupus erythematosus autoantigens with a peptide array |
| Q64258617 | Sources of Pathogenic Nucleic Acids in Systemic Lupus Erythematosus |
| Q38130443 | Targeted therapies in systemic lupus erythematosus |
| Q51838886 | Treatment options in paraneoplastic disorders of the peripheral nervous system. |
Search more.